Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer
- 31 October 2011
- journal article
- research article
- Published by Elsevier BV in Clinical Breast Cancer
- Vol. 11 (5), 306-311
- https://doi.org/10.1016/j.clbc.2011.03.021
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Activity of dasatinib with chemotherapy in triple-negative breast cancer cellsJournal of Clinical Oncology, 2009
- Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530Oncogene, 2008
- Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient SelectionCancer Research, 2007
- Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitroBreast Cancer Research and Treatment, 2007
- p27 Phosphorylation by Src Regulates Inhibition of Cyclin E-Cdk2Cell, 2007
- pp60c-src activation in lung adenocarcinomaEuropean Journal of Cancer, 2003
- Activated Src Protein Tyrosine Kinase Is Overexpressed in Late-Stage Human Ovarian CancersGynecologic Oncology, 2003
- Src family kinases in tumor progression and metastasisCancer and Metastasis Reviews, 2003
- Activation of c-Src is Inversely Correlated with Biological Aggressiveness of Breast CarcinomaBreast Cancer Research and Treatment, 2002
- Activation of Src kinase in primary colorectal carcinomaCancer, 2002